Identification of Potent and Long-Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The insulin-like peptide human relaxin-2 was identified as a hormone that, among other biological functions, mediates the hemodynamic changes occurring during pregnancy. Recombinant relaxin-2 (serelaxin) has shown beneficial effects in acute heart failure, but its full therapeutic potential has been hampered by its short half-life and the need for intravenous administration limiting its use to intensive care units. In this study, we report the development of long-acting potent single-chain relaxin peptide mimetics. Modifications in the B-chain of relaxin, such as the introduction of specific mutations and the trimming of the sequence to an optimal size, resulted in potent, structurally simplified peptide agonists of the relaxin receptor Relaxin Family Peptide Receptor 1 (RXFP1) ( e.g. , 54 ). Introduction of suitable spacers and fatty acids led to the identification of single-chain lipidated peptide agonists of RXFP1, with sub-nanomolar activity, high subcutaneous bioavailability, extended half-lives, and in vivo efficacy ( e.g. , 64 ).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Micsonai, A., Wien, F., Bulyáki, É., Kun, J., Moussong, É., Lee, Y.-H., Goto, Y., Réfrégiers, M., & Kardos, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky497 · Cited by 1,131
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
N‐ and C‐capping preferences for all 20 amino acids in α‐helical peptides
Doig, A. J., & Baldwin, R. L. (1995) · Protein Science · doi:10.1002/pro.5560040708 · Cited by 319
. Effects of serelaxin in patients with acute heart failure
Metra, M., Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg, B. H., Pang, P. S., Ponikowski, P., Voors, A. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1801291 · Cited by 282
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244
Benedetti, E., Bavoso, A., Di Blasio, B., Pavone, V, Pedone, C., Toniolo, C., & Bonora, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7951 · Cited by 183
A review of lipidation in the development of advanced protein and peptide therapeutics
Menacho‐Melgar, R., Decker, J. S., Hennigan, J. N., & Lynch, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.032 · Cited by 171
Forming stable helical peptides using natural and artificial amino acids
Andrews, M. J. I., & Tabor, A. B. (1999) · Tetrahedron · doi:10.1016/s0040-4020(99)00678-x · Cited by 168
Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives
Bech, E. M., Pedersen, S. L., & Jensen, K. J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00226 · Cited by 153
Halls, M. L., Bathgate, R. A. D., Sutton, S. W., Dschietzig, T. B., & Summers, R. J. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009472 · Cited by 143
Research works printed but not linked: 1
- Larsen B. D., 2001, Proceedings of the Twenty-Sixth European Peptide Symposium, September 10–15, 2000, 37
Cited by
Khavinson, V., Linkova, N. S., Dyatlova, A., Кантемирова, Р. К., & Kozlov, K. L. (2022) · Cells · doi:10.3390/cells12010106 · Cited by 88
Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions
Samuel, C. S., & Bennett, R. G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114884 · Cited by 34
Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure
Verdino, P., Lee, S. L., Cooper, F. N., Cottle, S. R., Grealish, P. F., Hu, C. C., Meyer, C. M., Lin, J., Copeland, V., Porter, G., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16055 · Cited by 33
Single‐Shot Solid‐Phase Synthesis of Full‐Length H2 Relaxin Disulfide Surrogates
Zhao, R. J., Shi, P., Cui, J., Shi, C., Wei, X., Luo, J., Xia, Z., Shi, W., Zhou, Y., Tang, J., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202216365 · Cited by 26
Illiano, S., Poirier, B., Minoletti, C., Pasquier, O., Riva, L., Chénedé, X., Menguy, I., Guillotel, M., Prigent, P., Claire, S. L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24716-2 · Cited by 20
Self-citationPotent Lys Patch-Containing Stapled Peptides Targeting PCSK9
Bourbiaux, K., Legrand, B., Verdié, P., Mallart, S., Manette, G., Minoletti, C., Stepp, J. D., Prigent, P., Bail, J.-C. L., Gauzy, L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02051 · Cited by 17
Self-citationKaushal, N., Attarwala, H. Z., Iqbal, M. J., Saini, R., Van, L. M., & Liang, M. (2024) · Clinical and Translational Science · doi:10.1111/cts.13894 · Cited by 14
Subcutaneous catabolism of peptide therapeutics: bioanalytical approaches and ADME considerations
Esposito, S., Orsatti, L., & Pucci, V. (2022) · Xenobiotica · doi:10.1080/00498254.2022.2119180 · Cited by 13
Self-citationEngineering and Characterization of a Long-Half-Life Relaxin Receptor RXFP1 Agonist
Erlandson, S. C., Wang, J., Jiang, H., Osei‐Owusu, J., Rockman, H. A., & Kruse, A. C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00368 · Cited by 13
Granberg, K. L., Sakamaki, S., Fuchigami, R., Niwa, Y., Fujio, M., Kato, H., Bergström, F., Larsson, N., Persson, M., Villar, I. C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02183 · Cited by 13
Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions
Nourmahnad, A., Shariyate, M. J., Khak, M., Grinstaff, M. W., Nazarian, A., & Rodriguez, E. K. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116273 · Cited by 12
Praveen, P., Wang, C., Handley, T. N. G., Wu, H., Samuel, C. S., Bathgate, R. A. D., & Hossain, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076616 · Cited by 12
R2R01: A long‐acting single‐chain peptide agonist of RXFP1 for renal and cardiovascular diseases
Poirier, B., Pasquier, O., Chénedé, X., Corbier, A., Prigent, P., Azam, A., Bernard, C., Guillotel, M., Gillot, F., Riva, L., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16338 · Cited by 12
Self-citationEsposito, S., Krick, A., Pasquier, O., Bonche, F., Ingenito, R., Magotti, P., Bianchi, E., Monteagudo, E. S., Gallo, M. L., Cicero, D. O., et al. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115256 · Cited by 10
Self-citationEmergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways
Liu, Z., Zhang, X., Wang, Y., Tai, Y., Yao, X., & Midgley, A. C. (2023) · Biomolecules · doi:10.3390/biom13081179 · Cited by 9
Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology
Agoulnik, I. U., Kaftanovskaya, E. M., Myhr, C. B., Bathgate, R. A. D., Kočan, M., Peng, Y., Lindsay, R. M., DiStefano, P. S., & Agoulnik, A. I. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116401 · Cited by 7
Bąchor, U., Lizak, A., Bąchor, R., & Mą̨czyński, M. (2022) · Molecules · doi:10.3390/molecules27175612 · Cited by 6
Further Developments towards a Minimal Potent Derivative of Human Relaxin-2
Handley, T. N. G., Praveen, P., Tailhades, J., Wu, H., Bathgate, R. A. D., & Hossain, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612670 · Cited by 6
Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension
Chunduri, P., Patel, S. A., & Levick, S. P. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.04.002 · Cited by 5
Devasia, A. G., Shanmugham, M., Ramasamy, A., Bellanger, S., Parry, L. J., & Leo, C. H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116507 · Cited by 4
D’Ercole, A., Nistri, S., Pacini, L., Carotenuto, A., Santoro, F., Papini, A. M., Bathgate, R. A. D., Bani, D., & Rovero, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.942178 · Cited by 4
Single‐Shot Solid‐Phase Synthesis of Full‐Length H2 Relaxin Disulfide Surrogates
Zhao, R. J., Shi, P., Cui, J., Shi, C., Wei, X., Luo, J., Xia, Z., Shi, W., Zhou, Y., Tang, J., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202216365 · Cited by 2
Long-acting relaxin analogues: a novel tool in cardiology
Wołowiec, Ł., Jaśniak, A., Osiak, J., Czaplińska, D., Szymczak, A., Pęcherz, J. A., & Grześk, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1626469 · Cited by 2
Revivifying research on relaxin receptor-targeted therapy for cardiovascular diseases
Du, X.-J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf057 · Cited by 1
Yu, J., Kang, X., Chang, R., Zhang, C., Sl, Y., Chen, L., Wang, X., Hu, B., Wang, Z., Gong, L., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704023 · Cited by 1
Mallart, S., Ingenito, R., Magotti, P., Bresciani, A., Marco, A. D., Esposito, S., Monteagudo, E. S., Caretti, F., Orsatti, L., Santoprete, A., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03085 · Cited by 1
Self-citationWilhelmi, T. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10076 · Cited by 1
Relaxin family peptide receptors in GtoPdb v.2023.1
Agoulnik, A. I., Bathgate, R. A. D., Dschietzig, T. B., Gundlach, A. L., Halls, M. L., Smith, C. M., & Summers, R. J. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f60/2023.1
Relaxin family peptide receptors in GtoPdb v.2025.3
Agoulnik, A. I., Bathgate, R. A. D., Dschietzig, T. B., Gundlach, A. L., Halls, M. L., Smith, C. M., & Summers, R. J. (2025) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f60/2025.3
BindingDB Entry 50015095: Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9.
BindingDB (2023) · UC San Diego · doi:10.7270/q27d301h
Metadata
- Authors
- Mallart, S., Ingenito, R., Bianchi, E., Bresciani, A., Esposito, S., Gallo, M., Magotti, P., Monteagudo, E., Orsatti, L., Roversi, D., Santoprete, A., Tucci, F., Veneziano, M., Bartsch, R., Boehm, C., Brasseur, D., Bruneau, P., Corbier, A., Froissant, J., Gauzy-Lazo, L., Gervat, V., Marguet, F., Menguy, I., Minoletti, C., Nicolas, M.-F., Pasquier, O., Poirier, B., Raux, A., Riva, L., Janiak, P., Strobel, H., Duclos, O., & Illiano, S.
- Affiliations
- Sanofi (France) (FR)
- IRBM (IT)
- DMPK, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
- Industrial Affairs, iCMC, Sanofi-Aventis R&D, Industriepark Höchst, Frankfurt 65926, Germany
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
- Cardio-Vascular and metabolism, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
- Corresponding author
- Mallart, Sergio
- ORCID
- Mallart, Sergio
- Ingenito, Raffaele
- Bianchi, Elisabetta
- Bresciani, Alberto
- Esposito, Simone
- Gallo, Mariana
- Magotti, Paola
- Monteagudo, Edith
- Orsatti, Laura
- Roversi, Daniela
- Santoprete, Alessia
- Tucci, Federica
- Gauzy-Lazo, Laurence
- Marguet, Frank
- Minoletti, Claire
- Nicolas, Marie-Françoise
- Poirier, Bruno
- Janiak, Philip
- Duclos, Olivier
- Illiano, Stephane
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-02-08
- Volume
- 64
- Issue
- 4
- Pages
- 2139-2150
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3128803349
- Cited by
- 29
- References
- 32
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 8 · 2021: 2
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy-related medical research
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- relaxin-2, peptidomimetics, RXFP1, lipidated peptides, subcutaneous bioavailability, acute heart failure, cardiovascular disease
- MeSH terms
- Amino Acid Sequence, Animals, Cardiovascular Diseases, Half-Life, Humans, Male, Mutation, Relaxin, Structure-Activity Relationship, Molecular Structure, Rats, Sprague-Dawley, Receptors, Peptide, Protein Subunits, Receptors, G-Protein-Coupled, Cell Line, Tumor, Rats, Lipopeptides, Molecular Dynamics Simulation, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.